Methods for treating neuropathic pain using heteroarylmethanesulfonamides

• US 6,489,350 B1
• Filed: 09/15/2000
• Issued: 12/03/2002
• Est. Priority Date: 09/15/1999
• Status: Expired due to Fees

• Current Assignee: Eisai Incorporated (Eisai Medical Research Incorporated)
• Original Assignee: Elan Pharmaceuticals Incorporated (Perrigo Company PLC)
• Inventors: Benedyk, Mark J.
• Primary Examiner(s): Spivack, Phyllis G.
• Application Number:
  US09/663,107
• Time in Patent Office: 809 Days
• Field of Search: 514/375, 514/379
• US Class Current: 514/375
• CPC Class Codes: A61K 31/423 condensed with carbocyclic rings
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids

Abstract

A method of treating neuropathic pain and its progression is disclosed comprising administering to a subject a compound of formula

wherein R is hydrogen or a halogen atom, R₂ and R₃ are the same or different and are each hydrogen or a straight or branched alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atoms, provided that the methanesulfonamide group is bonded to the carbon atom of either X and Y, exemplified by zonisamide.

Claims

1. A method for the treatment of neuropathic pain in a mammal comprising administering to said mammal in need of such treatment an efficacious amount of a compound of formula I

wherein R is hydrogen or a halogen atom, R₂ and R₃ are the same or different and are each hydrogen or a straight or branched alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atoms, provided that the methanesulfonamido group is bonded to the carbon atom represented by X or Y, provided the neuropathic pain is not trigeminal neuralgia.

2. The method of claim 1 wherein said compound is 1,2-benzisoxazole-3-methanesulfonamide zonisamide.

3. The method of claim 1 wherein the efficacious amount is in a range of 1 mg/kg to 400 mg/kg per day.

4. The method of claim 3 wherein the compound is administered orally.

5. The method of claim 4 wherein said method further comprises administering the compound in a unit dosage form.

6. The method of claim 1 wherein said administration is by perineural application.

7. The method of claim 1 wherein said the compound of formula I is administered topically to a skin region having or manifesting the neuropathic pain.

8. The method of claim 1 wherein the compound is administered orally.

9. The method of claim 1 wherein the neuropathic pain is selected from the group consisting of diabetic neuropathy, optic neuropathy, neuropathy secondary to nerve trauma, post herpetic neuralgia, reflex sympathetic dystrophy, cancer pain and AIDS-related neuropathy.

10. The method of claim 9 wherein said compound is 1,2-benzisoxazole-3-methanesulfonamide zonisamide.

11. The method of claim 10 wherein the efficacious amount of zonisamide is in a range of 1 mg/kg to 400 mg/kg per day.

12. The method of claim 11 wherein the compound is administered orally.

13. The method of claim 12 wherein said method further comprises administering the compound in a unit dosage form.

14. The method of claim 9 wherein said administration is by perineural application.

15. The method of claim 9 wherein said the compound is administered topically to a skin region having or manifesting the neuropatbic pain.

16. The method of claim 9 wherein the compound is administered orally.

17. A method for the treatment of neuropathic pain in a skin region of a mammal comprising, a transdermal patch providing an efficacious amount of a compound of formula I

wherein R is hydrogen or a halogen atom, R₂ and R₃ are the same or different and are each hydrogen or a straight or branched alkyl having 1 to 3 carbon atoms, and one of X and Y is a carbon atom and another is a nitrogen atoms, provided that the methanesulfonarnido group is bonded to the carbon atom of either X and Y applied to the having or manifesting the neuropathic pain, provided that the neuropathic pain is not trigeminal neuralgia.

18. The method of claim 17 wherein the compound of formula I is zonisamide.